Mark R. Gilbert, MD
Professor & Deputy Chair
Department of Neuro-Oncology
University of Texas MD Anderson Cancer Center
David A. Reardon, MD
Clinical Director, Medical Research
The Preston Robert Tisch Brain Tumor Center
Associate Professor of Surgery
Associate Professor of Pediatrics
Duke University Medical Center
Durham, North Carolina
John H. Suh, MD
Chairman, Department of Radiation Oncology
Brain Tumor Institute
Cleveland Clinic Foundation
William F. Regine, MD
Professor & Chair
Department of Radiation Oncology
University of Maryland School of Medicine
CME 1.25 hours
CREDIT FOR THIS PROGRAM IS AVAILABLE FOR PHYSICIANS, ONLY.
Although primary brain malignancies constitute a small percentage of cancers, they present a large challenge in treatment and management. Despite advances in neurosurgical and radiotherapeutic techniques, the prognosis remains dismal for most patients. There have been recent advances in treatment approaches for specific glial tumors that have increased overall survival. Hence, there is an increasing focus on developing specific treatment approaches for individual tumor types. This program examines five case histories, presenting patients with differing pathologies and prognoses. Cases include newly diagnosed glioblastoma multiforme (GBM), recurrent GBM, anaplastic gliomas, and low-grade gliomas. Each case is examined and discussed with the goal of determining the safest and most efficacious therapeutic option for that patient. State-of-the-art approaches in radiation, surgery and radiosurgery, chemotherapy, and combination chemoradiotherapy are discussed. Program Developer/Facilitator
. Target Audience
This educational activity is designed to meet the needs of radiation oncologists, neuro-oncologists, and other physicians interested in the treatment of primary gliomas.
Upon completion of this educational activity, the participant should be able to:
Describe approaches to the management of patients with newly diagnosed glioblastoma multiforme.
Explain the rationale and potential limitations of salvage strategy approaches in the treatment of patients with recurrent glioblastoma multiforme.
Assess the evolving management strategies for anaplastic gliomas.
Compare and contrast literature-based evidence describing the risks or benefits of early versus delayed radiotherapy in the management of low-grade gliomas.
It is the policy of AKH Inc. to ensure independence, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity.
Dr. Gilbert is on an advisory committee and speakers’ bureau for Schering-Plough Corporation. He intends to discuss unapproved and/or investigational uses of pharmacologic products.
Dr. Reardon is a consultant for EMD Pharmaceuticals; Novacea Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc. He is also on an advisory committee for Novartis Pharmaceuticals and is on a speakers’ bureau for Schering-Plough Corporation. He intends to discuss unapproved and/or investigational uses of pharmacologic products.
Dr. Suh is on a speakers’ bureau for Schering-Plough Corporation. He intends to discuss unapproved and/or investigational uses of pharmacologic products.
Dr. Regine is on a speakers’ bureau for Schering-Plough Corporation. He intends to discuss unapproved and/or investigational uses of pharmacologic products.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Incorporated. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credits. Physicians should only claim credit commensurate with the extent of their participation in the activity. TM
Participants must successfully complete the post-test (70% or higher) and submit an evaluation to receive credit. It should take approximately 75 minutes minutes to view the program and complete the post-test. There are no fees to participate and receive credit.
Commercial Support Statements
This activity is supported by an educational grant from Schering-Plough.
Please turn off all pop-up blockers and click on the "Start Program" icon. If you are not already logged in to the site, this will bring you to the login/registration page where you will be able to register as a new cmecorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
The next screen will permit you to check for or download the Flash player required to run this program. Clicking on the "slides" button on this screen will begin the program presentation. Clicking on the "Q and A" button will bring you to the pre-recording question-and-answer session. The program, Q and A, post-test, and evaluation will take approximately 75 minutes to complete.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME certificate.
None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this publication are those of the faculty contributors and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or Schering-Plough. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other healthcare professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.